IXHL - PRISM Mid-Day Movers: Biotech Volatility and Global Health Advances
2025-05-19 14:30:46 ET
Applied Therapeutics Drops 19% Despite New Data Presentation
Applied Therapeutics Inc. ( APLT ) fell 19.12%, pulling down the PRISM Emerging Pharmaceuticals Index , after releasing 12- and 24-month clinical data from its INSPIRE Phase 2/3 trial for govorestat , an investigational treatment for CMT-SORD, a rare neuromuscular disease. While the company shared positive long-term trends such as sustained reductions in blood sorbitol levels and improvements in patient-reported outcomes, the primary endpoint at 12 months did not reach statistical significance. The company is still planning a New Drug Application submission later this year.
BrainStorm Gains 18% on FDA Clearance for ALS Trial
BrainStorm Cell Therapeutics Inc. ( BCLI ) climbed 18.18%, lifting the PRISM Emerging Global Health Index , after receiving FDA clearance to begin a new Phase 3b trial of its investigational ALS treatment, NurOwn(R) . The 200-participant study will assess the treatment's effect on ALS functional ratings, following prior studies and regulatory feedback. With enrollment expected to begin soon, BrainStorm continues to explore funding options to support the trial's launch and completion.
Other PRISM Mid-Day Movers:
- Incannex Healthcare Inc. ( IXHL ): -20.31%
- Helius Medical Technologies, Inc. ( HSDT ): +14.72%
- Arqit Quantum Inc. ( ARQQ ): +19.05%
- Reviva Pharmaceuticals Holdings, Inc. ( RVPH ): +14.20%
The post PRISM Mid-Day Movers: Biotech Volatility and Global Health Advances appeared first on PRISM MarketView .
COMTEX_465634010/2927/2025-05-19T13:30:46